• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>CNS & Neurological Disorders - Drug Targets >The NMDA Receptor as a Therapeutic Target in Major Depressive Disorder
【24h】

The NMDA Receptor as a Therapeutic Target in Major Depressive Disorder

机译：NMDA受体作为重度抑郁症的治疗靶标

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Ample evidence indicates that glutamate homeostasis and neurotransmission are disrupted in major depressive disorder; but the nature of this disruption and the mechanisms by which it contributes to the syndrome are unclear. Likewise, the effect of existing antidepressants on glutamate is unclear, as is the potential of drugs directly targeting glutamatergic neurotransmission to act as novel antidepressant medications. These are areas of active research. Here we review current knowledge of the contribution of the NMDA receptor, one of the several types of glutamate receptor, to depression and its treatment. Several lines of evidence, in humans and in animal models, support the contention that neurotransmission via the NMDA receptor is dysregulated in depression. Drugs that target the NMDA receptor have shown antidepressant properties in both clinical and preclinical studies. Nevertheless, other effects of such medications, including both cognitive side effects and their psychotomimetic properties, complicate such an application and represent a challenge to the development of clinically useful agents.
机译：大量证据表明，重度抑郁症患者的谷氨酸稳态和神经传递受到破坏。但是这种破坏的性质以及导致这种综合征的机制尚不清楚。同样，尚不清楚现有抗抑郁药对谷氨酸的作用，直接靶向谷氨酸能神经传递的药物作为新型抗抑郁药的潜力也不清楚。这些是积极研究的领域。在这里，我们回顾当前的知识，NMDA受体，几种类型的谷氨酸受体之一，对抑郁症及其治疗的贡献。在人类和动物模型中，有几条证据支持通过NMDA受体进行神经传递在抑郁症中失调的观点。在临床和临床前研究中，靶向NMDA受体的药物均显示出抗抑郁特性。然而，此类药物的其他作用，包括认知副作用和拟精神病学性质，都使这种应用复杂化，并代表了对临床有用药物开发的挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号